Drug Type Synthetic peptide |
Synonyms |
Target |
Action agonists |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | China | 29 Nov 2024 | |
Obesity | Phase 3 | China | 28 Oct 2024 | |
Overweight | Phase 3 | China | 28 Oct 2024 |
CTR20233198 (NEWS) Manual | Phase 2 | 120 | (5mg) | (rbunmbbbha) = dcbmylbdbq axirvrtgfz (hlelgznbbd ) View more | Positive | 14 Oct 2024 | |
(10mg) | (rbunmbbbha) = ftiipoycoa axirvrtgfz (hlelgznbbd ) View more | ||||||
NEWS Manual | Phase 2 | 64 | (ogexssjnmi) = tqxedijbkg chpvooexkp (vqqfhcjbax ) Met View more | Positive | 26 Aug 2024 | ||
(ogexssjnmi) = wggtzgckbb chpvooexkp (vqqfhcjbax ) Met View more | |||||||
CTR20232464 (NEWS) Manual | Phase 2 | - | (prfykfzdci) = 各剂量组受试者HbA1c、空腹血糖、餐后2h血糖等指标均较基线有显著降低。 xqdolarqkk (myzvrdwiad ) View more | Positive | 09 Jul 2024 | ||
CTR20230120 (ADA2024) Manual | Phase 1 | 40 | (ivxbbtydtn) = gastrointestinal adverse events like decreased appetite, nausea, abdominal distension, vomiting, and diarrhea were most common, all mild to moderate. ngyapmzvga (bqfjqfkary ) View more | Positive | 21 Jun 2024 |